Agilent Technologies Secures EU Nod for Ovarian Cancer Diagnostic—Can Label Expansion Drive Growth Amid Danaher Pressure?
Agilent Technologies Inc. (NYSE: A) has extended its diagnostics franchise into a critical oncology niche. On July 23, European regulators certified the company’s PD-L1 IHC 22C3 pharmDx test (Code SK006) as a companion diagnostic for epithelial ovarian, fallopian tube, and primary peritoneal carcinoma. The approval enables pathologists to identify patients who may benefit from Merck’s … Read more





